Your browser doesn't support javascript.
loading
Real-world use of once-weekly semaglutide in patients with type 2 diabetes: pooled analysis of data from four SURE studies by baseline characteristic subgroups.
Yale, Jean-François; Bodholdt, Ulrik; Catarig, Andrei-Mircea; Catrina, Sergiu; Clark, Alice; Ekberg, Neda Rajamand; Erhan, Umut; Holmes, Patrick; Knudsen, Søren Tang; Liutkus, Joanne; Sathyapalan, Thozhukat; Schultes, Bernd; Rudofsky, Gottfried.
Affiliation
  • Yale JF; Royal Victoria Hospital, McGill University Health Centre, Montreal, Quebec, Canada jean-francois.yale@mcgill.ca.
  • Bodholdt U; Kastruplægerne, Kastrup, Denmark.
  • Catarig AM; Novo Nordisk AS, Søborg, Denmark.
  • Catrina S; Karolinska Institutet, Stockholm, Sweden.
  • Clark A; Center for Diabetes, Academic Specialist Center, Stockholm, Sweden.
  • Ekberg NR; Novo Nordisk AS, Søborg, Denmark.
  • Erhan U; Karolinska Institutet, Stockholm, Sweden.
  • Holmes P; Novo Nordisk AS, Søborg, Denmark.
  • Knudsen ST; St. George's Medical Practice, Darlington, UK.
  • Liutkus J; Steno Diabetes Center Aarhus, Aarhus University Hospital, Aarhus, Denmark.
  • Sathyapalan T; Joanne F. Liutkus Medicine Professional Corporation, Cambridge, Ontario, Canada.
  • Schultes B; Academic Diabetes, Endocrinology and Metabolism, University of Hull, Hull, UK.
  • Rudofsky G; Metabolic Center St. Gallen, friendlyDocs, St. Gallen, Switzerland.
BMJ Open Diabetes Res Care ; 10(2)2022 04.
Article in En | MEDLINE | ID: mdl-35383100
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Diabetes Mellitus, Type 2 Type of study: Prognostic_studies Limits: Aged / Humans Language: En Year: 2022 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Diabetes Mellitus, Type 2 Type of study: Prognostic_studies Limits: Aged / Humans Language: En Year: 2022 Type: Article